Dimerix Ltd has released a press release.
First Paediatric Patient Recruited for ACTION3
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Dimerix
- Dimerix enters Development and License Agreement for Japan
- DMX-200 ACTION3 Phase 3 Trial Part 2 Recruitment Complete
- Dimerix Receives $7.9M R&D Tax Incentive Rebate
- NEPTUNE Study Network to Enhance Phase 3 Recruitment in US
- Project PARASOL Update & Medical Advisory Board Appointment
Later from Dimerix
- Half-Year Financial Report & Appendix 4D - 31 December 2024
- Dimerix receives initial upfront payment from FUSO
- S&P DJI Announces March 2025 Quarterly Rebalance
- FDA confirms Proteinuria as Primary Endpoint for US approval
- Trading Halt
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix